Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug BHV-1400 tested for kidney disease

NCT ID NCT07054684

Recruiting now Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 participants with confirmed IgA nephropathy will receive the drug subcutaneously. The main goal is to check for side effects and lab abnormalities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BHV-1400
What this could lead to
If it works, this could point toward a new treatment option for IgA nephropathy, a kidney disease that currently has limited therapies.
What could go wrong
This is a very early Phase 1 trial with only 20 people, focused on safety, not effectiveness. Many drugs fail at this stage, and it may not lead to a real treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome glomerulonephritis IgA glomerulonephritis kidney disorder nephritis proteinuria urinary system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site-001

    RECRUITING

    Farmington, Connecticut, 06030, United States

  • Site-002

    RECRUITING

    Dakota Dunes, South Dakota, 57049, United States

  • Site-003

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • Site-004

    RECRUITING

    Houston, Texas, 77099, United States

  • Site-005

    RECRUITING

    Pembroke Pines, Florida, 33029, United States

  • Site-006

    RECRUITING

    Chesterfield, Missouri, 63017, United States

  • Site-007

    RECRUITING

    Leicester, LE5 4PW, United Kingdom

  • Site-008

    RECRUITING

    Lawrenceville, Georgia, 30046, United States

  • Site-009

    RECRUITING

    Hinsdale, Illinois, 60521, United States

  • Site-011

    RECRUITING

    Miami Lakes, Florida, 33172, United States

  • Site-012

    RECRUITING

    Indianapolis, Indiana, 46268, United States

  • Site-013

    RECRUITING

    Orlando, Florida, 32806, United States

  • Site-014

    RECRUITING

    Houston, Texas, 77027, United States

  • Site-015

    RECRUITING

    Shelby, Michigan, 48316, United States

  • Site-016

    RECRUITING

    Salt Lake City, Utah, 84115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.